BridgeMD
New treatment option for Nasal Obstruction
Official title Nasal Obstruction With Oxymetazoline and Corticosteroids
ClinicalTrials.gov ID: NCT06830109
What this study is testing
What is Oxymetazoline Nasal Spray?
Oxymetazoline Nasal Spray is an investigational medicine, given as an once-daily, being studied as a potential treatment for nasal obstruction.
Also referred to as Afrin (commercial name for oxymetazoline hydrochloride).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to examine the efficacy and safety of commination oxymetazoline/intranasal steroids for long-term management of chronic nasal obstruction that is recalcitrant to the current standard of care. The investigators hypothesize that combination treatment with oxymetazoline and intranasal corticosteroid spray will provide a larger reduction in nasal obstruction than intranasal corticosteroid alone for patients suffering from chronic nasal obstruction, and there will not be occurrences of rhinitis medicamentosa.
- Phase 2: a mid-size study of how well it works
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- males and females ages 18 years or older
- have a history of nasal obstruction
- have failed a trial of topical steroids (that included at least 1 month of daily use)
- ability to read, write, and understand English
- either do not desire surgery or are poor surgical candidates due to medical comorbidities.
You likely can't join if
- Any history of sinonasal mass/tumor
- Any history of nasal polyps
- a known history of chronic sinusitis
- an allergy to oxymetazoline
- or who have any medical contraindication to oxymetazoline use, such as pulmonary hypertension.
See the full eligibility criteria
- males and females ages 18 years or older
- have a history of nasal obstruction
- have failed a trial of topical steroids (that included at least 1 month of daily use)
- ability to read, write, and understand English
- either do not desire surgery or are poor surgical candidates due to medical comorbidities.
- Patients who have had prior use of oxymetazoline or other nasal decongestants are eligible for the study but must have stopped usage 4 weeks prior to randomization.
- Must be willing to stop using any other nasal sprays, besides saline, and oral decongestants.
- Any history of sinonasal mass/tumor
- Any history of nasal polyps
- a known history of chronic sinusitis
- an allergy to oxymetazoline
- or who have any medical contraindication to oxymetazoline use, such as pulmonary hypertension.
The study team makes the final eligibility decision.
Where it's taking place
- St Louis, Missouri, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include St Louis, Missouri, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.